The CDK inhibitors in cancer research and therapy

被引：193

作者：

Cicenas, Jonas ^{[1
,2
]}

Valius, Mindaugas ^{[3
]}

机构：

[1] Univ Fribourg, Inst Anat, Dept Med, CH-1700 Fribourg, Switzerland

[2] MAP Kinase Resource, Bern, Switzerland

[3] Lithuania Acad Sci, Inst Biochem, Dept Dev Biol, LT-232600 Vilnius, Lithuania

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2011年 / 137卷 / 10期

关键词：

CDK; Kinases; Small-molecule inhibitors; Cancer; Cell cycle; DEPENDENT KINASE INHIBITOR; ADVANCED SOLID TUMORS; CELL LUNG-CANCER; PHASE-II TRIAL; CHRONIC LYMPHOCYTIC-LEUKEMIA; GROWTH-FACTOR RECEPTOR; ACTIVITY IN-VIVO; BREAST-CANCER; CARCINOMA-CELLS; POOR-PROGNOSIS;

D O I：

10.1007/s00432-011-1039-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chemical compounds that interfere with an enzymatic function of kinases are useful for gaining insight into the complicated biochemical processes in mammalian cells. Cyclin-dependent kinases (CDK) play an essential role in the control of the cell cycle and/or proliferation. These kinases as well as their regulators are frequently deregulated in diVerent human tumors. Aberrations in CDK activity have also been observed in viral infections, Alzheimer's, Parkinson's diseases, ischemia and some proliferative disorders. This led to an intensive search for small-molecule CDK inhibitors not only for research purposes, but also for therapeutic applications. Here, we discuss seventeen CDK inhibitors and their use in cancer research or therapy. This review should help researchers to decide which inhibitor is best suited for the specific purpose of their research. For this purpose, the targets, commercial availability and IC50 values are provided for each inhibitor. The review will also provide an overview of the clinical studies performed with some of these inhibitors.

引用

页码：1409 / 1418

页数：10

共 88 条

[1] Phase II study of flavopiridol in patients with advanced colorectal cancer [J].

Aklilu, M ;

Kindler, HL ;

Donehower, RC ;

Mani, S ;

Vokes, EE .

ANNALS OF ONCOLOGY, 2003, 14 (08) :1270-1273

[2]

Arguello F, 1998, BLOOD, V91, P2482

[3] Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles [J].

Arris, CE ;

Boyle, FT ;

Calvert, AH ;

Curtin, NJ ;

Endicott, JA ;

Garman, EF ;

Gibson, AE ;

Golding, BT ;

Grant, S ;

Griffin, RJ ;

Jewsbury, P ;

Johnson, LN ;

Lawrie, AM ;

Newell, DR ;

Noble, MEM ;

Sausville, EA ;

Schultz, R ;

Yu, W .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (15) :2797-2804

[4] A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days [J].

Benson, C. ;

White, J. ;

De Bono, J. ;

O'Donnell, A. ;

Raynaud, F. ;

Cruickshank, C. ;

McGrath, H. ;

Walton, M. ;

Workman, P. ;

Kaye, S. ;

Cassidy, J. ;

Gianella-Borradori, A. ;

Judson, I. ;

Twelves, C. .

BRITISH JOURNAL OF CANCER, 2007, 96 (01) :29-37

[5] Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen [J].

Bergqvist, Jenny ;

Elmberger, Goran ;

Ohd, John ;

Linderholm, Barbro ;

Bjohle, Judith ;

Hellborg, Henrik ;

Nordgren, Hans ;

Borg, Anna-Lena ;

Skoog, Lambert ;

Bergh, Jonas .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) :1104-1112

[6] Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients [J].

Berkofsky-Fessler, Windy ;

Nguyen, Tri Q. ;

Delmar, Paul ;

Molnos, Juliette ;

Kanwal, Charu ;

DePinto, Wanda ;

Rosinski, James ;

McLoughlin, Patricia ;

Ritland, Steve ;

DeMario, Mark ;

Tobon, Krishna ;

Reidhaar-Olson, John F. ;

Rueger, Ruediger ;

Hilton, Holly .

MOLECULAR CANCER THERAPEUTICS, 2009, 8 (09) :2517-2525

[7] Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points [J].

Bible, KC ;

Lensing, JL ;

Nelson, SA ;

Lee, YK ;

Reid, JM ;

Ames, MM ;

Isham, CR ;

Piens, J ;

Rubin, SL ;

Rubin, J ;

Kaufmann, SH ;

Atherton, PJ ;

Sloan, JA ;

Daiss, MK ;

Adjei, AA ;

Erlichman, C .

CLINICAL CANCER RESEARCH, 2005, 11 (16) :5935-5941

[8] Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias [J].

Blum, William ;

Phelps, Mitch A. ;

Klisovic, Rebecca B. ;

Rozewski, Darlene M. ;

Ni, Wenjun ;

Albanese, Katie A. ;

Rovin, Brad ;

Kefauver, Cheryl ;

Devine, Steven M. ;

Lucas, David M. ;

Johnson, Amy ;

Schaaf, Larry J. ;

Byrd, John C. ;

Marcucci, Guido ;

Greyer, Michael R. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (07) :1098-1105

[9] Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma [J].

Burdette-Radoux, S ;

Tozer, RG ;

Lohmann, RC ;

Quirt, I ;

Ernst, DS ;

Walsh, W ;

Wainman, N ;

Colevas, AD ;

Eisenhauer, EA .

INVESTIGATIONAL NEW DRUGS, 2004, 22 (03) :315-322

[10]

Carlson BA, 1996, CANCER RES, V56, P2973

← 1 2 3 4 5 6 7 8 9 →